RBC Capital Maintains Outperform on Xylem, Raises Price Target to $159

Benzinga Newsdesk www.benzinga.com Positive 90.7%

Neg 0% Neu 0% Pos 90.7%

RBC Capital analyst Deane Dray maintains Xylem (NYSE:XYL) with a Outperform and raises the price target from $157 to $159.